Telix Pharmaceuticals Limited (TLX)

Market Cap	5.40B
Revenue (ttm)	484.69M
Net Income (ttm)	30.89M
Shares Out	329.55M
EPS (ttm)	0.09
PE Ratio	174.90
Forward PE	45.64
Dividend	n/a
Ex-Dividend Date	n/a

Volume	21,786
Open	16.03
Previous Close	16.40
Day's Range	15.98 - 16.12
52-Week Range	13.61 - 30.36
Beta	2.38
Analysts	Strong Buy
Price Target	22.00 (+37.41%)
Earnings Date	n/a

About TLX

Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals for cancer and rare diseases. The company operates through three segments: Therapeutics, Precision Medicine, and Telix Manufacturing Solutions. It offers Illuccix for the treatment of prostate cancer; and TLX66-CDx for the treatment of imaging osteomyelitis. The company’s products candidates include TLX591, a radio antibody-drug conjugate for the treatment of prostate ca...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2015
• Employees: 415
• Stock Exchange: NASDAQ
• Ticker Symbol: TLX
• Website: https://telixpharma.com

Financial Performance

In 2024, Telix Pharmaceuticals's revenue was 783.21 million, an increase of 55.85% compared to the previous year's 502.55 million. Earnings were 49.92 million, an increase of 857.95%.

Financial numbers in AUD

Analyst Forecast

According to 2 analysts, the average rating for TLX stock is "Strong Buy." The 12-month stock price forecast is $22.0, which is an increase of 37.41% from the latest price.

Price Target

$22.0

(37.41% upside)

Analyst Consensus: Strong Buy